Physician profile
Naima Vera-Sommers
NPI 1588999171
$11,403.25
in general payments reported to CMS, 2019-2025
61 companies · $4,766 in 2025
The $4,766 reported for 2025 was more than what 92% of Oncology (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $263).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $576 · 2022: $1,550 · 2023: $1,788 · 2024: $2,723 · 2025: $4,766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,492 · Long Term Medical Supply Or Device Loan: $1,780 · Education: $5.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,491.66 |
| Long Term Medical Supply Or Device Loan | $1,779.71 |
| Education | $5.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,368.04 | 2022-2025 | |
| Daiichi Sankyo INC. | $688.38 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Merck Sharp & Dohme LLC | $555.23 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $513.98 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $479.12 | 2021-2025 | Opdivo, Opdualag, Reblozyl |
| Rigel Pharmaceuticals, INC. | $439.93 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Astrazeneca Pharmaceuticals Lp | $394.06 | 2022-2025 | Calquence, Enhertu, Imfinzi |
| Incyte Corporation | $388.28 | 2022-2025 | Jakafi, Monjuvi, Jakafi |
| Eisai INC. | $387.79 | 2021-2025 | |
| Celgene Corporation | $343.68 | 2021-2025 | Reblozyl, Pomalyst, Pomalyst |
| Abbvie INC. | $326.60 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $307.82 | 2021-2024 | |
| Genzyme Corporation | $282.91 | 2021-2025 | |
| Genentech USA, INC. | $223.26 | 2021-2025 | Tecentriq |
| Gilead Sciences, INC. | $214.07 | 2021-2025 | Trodelvy |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $212.13 | 2023-2025 | Yescarta |
| Janssen Biotech, INC. | $210.86 | 2021-2025 | Darzalex, Tecvayli, Akeega |
| Astellas Pharma US INC | $187.11 | 2022-2025 | Padcev, Vyloy |
| Pharmacyclics LLC, An Abbvie Company | $181.11 | 2021-2023 | Imbruvica |
| Pharmaessentia USA Corporation | $177.65 | 2024-2025 | Besremi |
| Jazz Pharmaceuticals INC. | $177.49 | 2022 | |
| Glaxosmithkline, LLC. | $159.75 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Regeneron Healthcare Solutions, INC. | $135.43 | 2023-2025 | Libtayo |
| Sanofi US Services INC. | $131.90 | 2025 | |
| Seagen INC. | $127.50 | 2021-2023 | Tivdak |
| Blueprint Medicines Corporation | $124.67 | 2021 | |
| Array Biopharma INC | $117.50 | 2022-2025 | Braftovi, Mektovi, Tukysa |
| Penumbra, INC. | $113.59 | 2023 | Indigo System |
| Takeda Pharmaceuticals U.S.A., INC. | $104.41 | 2022-2025 | Alunbrig, Fruzaqla |
| Puma Biotechnology, INC. | $94.78 | 2021-2025 | |
| Lilly USA, LLC | $93.64 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Immunogen, INC. | $78.41 | 2023 | Elahere |
| Stemline Therapeutics INC. | $76.21 | 2023-2025 | Orserdu |
| Taiho Oncology, INC. | $76.16 | 2021-2025 | |
| Aveo Pharmaceuticals, INC. | $73.25 | 2022-2025 | Fotivda |
| Pharmacosmos Therapeutics INC. | $71.16 | 2023-2025 | Monoferric |
| Tersera Therapeutics LLC | $65.61 | 2023-2024 | Quzyttir, Zoladex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.01 | 2021-2025 | Gilotrif |
| Beone Medicines USA, INC. | $53.11 | 2025 | Brukinsa |
| Genentech, INC. | $47.92 | 2024 | |
| Amgen INC. | $40.54 | 2022 | |
| Deciphera Pharmaceuticals INC. | $38.72 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $36.09 | 2024-2025 | Onivyde, Somatuline Depot |
| Agios Pharmaceuticals, INC. | $35.73 | 2024-2025 | Pyrukynd |
| Legend Biotech USA INC. | $35.09 | 2024 | |
| Karyopharm Therapeutics INC. | $33.56 | 2021-2025 | Xpovio |
| Dendreon Pharmaceuticals LLC | $30.39 | 2025 | Provenge |
| Sobi, INC | $28.42 | 2022 | |
| Exelixis INC. | $27.88 | 2022 | |
| Genmab U.S., INC. | $24.98 | 2025 | Epkinly |
| Telix Pharmaceuticals | $24.57 | 2023 | Illuccix |
| Iovance Biotherapeutics, INC. | $24.36 | 2025 | Amtagvi |
| Syndax Pharmaceuticals, INC. | $21.86 | 2025 | |
| Mirati Therapeutics, INC. | $21.19 | 2023 | Krazati |
| Csl Behring | $20.29 | 2022 | |
| Ge Healthcare | $20.07 | 2022 | |
| Amag Pharmaceuticals, INC. | $19.51 | 2021 | |
| Sumitomo Pharma America, INC. | $16.40 | 2025 | Orgovyx |
| Alexion Pharmaceuticals, INC. | $15.48 | 2023 | Ultomiris |
| Myovant Sciences INC. | $13.95 | 2022 | |
| Adc Therapeutics America, INC. | $13.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naima Vera-Sommers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.